^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    DRUG:

    carboplatin

    i
    Other names: CBDCA, JM-8, JM8, NSC-241240, NSC-241240, NSC 241240, NSC-241-240
    Company:
    Generic mfg.
    Drug class:
    Tubulin polymerization promoter
    Related drugs:
    24h
    Vitamins in Gynecologic Malignancies. (PubMed, Nutrients)
    The use of drug combinations, such as 9cUAB130 with carboplatin and cisplatin with TAC-101, shows enhanced cytotoxic effects and reductions in ovarian tumor volume compared to single-drug treatments. Combining cisplatin with calcitriol and progesterone increases VDR expression, potentially enhancing the effectiveness of anticancer therapy in ovarian cancer...A balanced daily intake of vitamins is important, as both deficiency and excess can influence cancer development. It has been observed that there is a U-shaped relationship between group B vitamins and metabolic markers and clinical outcomes.
    Review • Journal
    |
    VDR (Vitamin D Receptor)
    |
    cisplatin • carboplatin
    3d
    A Study of Bemarituzumab Monotherapy and Combination With Other Anti-cancer Therapy in SqNSCLC With FGFR2b Overexpression (FORTITUDE-201) (clinicaltrials.gov)
    P1, N=180, Active, not recruiting, Amgen | Phase classification: P1b --> P1
    Phase classification
    |
    KRAS (KRAS proto-oncogene GTPase) • NTRK (Neurotrophic receptor tyrosine kinase)
    |
    KRAS mutation • KRAS G12C • KRAS G12 • FGFR2 overexpression • FGFR2b overexpression
    |
    Keytruda (pembrolizumab) • carboplatin • docetaxel • albumin-bound paclitaxel • bemarituzumab (AMG 552)
    3d
    Observation on the Therapeutic Effect of Huaier Granules in the Adjuvant Treatment of Non-small Cell Lung Cancer After Radical Surgery (clinicaltrials.gov)
    P=N/A, N=240, Recruiting, Liaoning Tumor Hospital & Institute | Not yet recruiting --> Recruiting | Initiation date: Dec 2023 --> Mar 2024
    Enrollment open • Trial initiation date • Surgery
    |
    CD4 (CD4 Molecule)
    |
    carboplatin • albumin-bound paclitaxel
    3d
    Study to Assess the Safety and Tolerability of a PARP Inhibitor in Combination With Carboplatin and/or Paclitaxel (clinicaltrials.gov)
    P1, N=189, Completed, AstraZeneca | Active, not recruiting --> Completed | Trial completion date: Dec 2024 --> Apr 2024
    Trial completion • Trial completion date • Combination therapy • Metastases
    |
    Lynparza (olaparib) • carboplatin • paclitaxel
    3d
    DeLLphi-303: First-Line Tarlatamab in Combination With Carboplatin, Etoposide, and PD-L1 Inhibitor in Subjects With Extensive Stage Small Cell Lung Cancer (ES-SCLC) (clinicaltrials.gov)
    P1, N=340, Recruiting, Amgen | Trial primary completion date: Dec 2025 --> Jan 2027
    Trial primary completion date • Combination therapy
    |
    Tecentriq (atezolizumab) • carboplatin • Imfinzi (durvalumab) • etoposide IV • tarlatamab (AMG 757)
    3d
    NEOLA: To Evaluate the Efficacy/Safety of Osimertinib Prior to CRT and Maintenance of it With Stage III, Unresectable NSCLC With EGFR Mutations (clinicaltrials.gov)
    P2, N=70, Recruiting, AstraZeneca | Not yet recruiting --> Recruiting
    Enrollment open
    |
    cisplatin • Tagrisso (osimertinib) • carboplatin • paclitaxel • pemetrexed
    3d
    Structure-bioactivity relationship study on anticancer Pd and Pt complexes with aliphatic glycine derivative ligands. (PubMed, Spectrochim Acta A Mol Biomol Spectrosc)
    Data revealed that all Pd/Pt complexes demonstrate higher anticancer activity than carboplatin, and complexes 3 and 4 are more cytotoxic than cisplatin against the HCT116 cell line, particularly against MCF7 cancerous cells. In addition, among all compounds, complex 4 has more anticancer ability than oxaliplatin...The binding capabilities of these complexes to DNA, as the main target in chemotherapy, occur through minor grooves and intercalate into DNA, which was done using absorption, fluorescence, and circular dichroism spectroscopy. Finally, the docking simulation study showed the mode of DNA bindings is in good agreement with the spectral binding data.
    Journal
    |
    PD-L1 (Programmed death ligand 1) • PD-L2 (Programmed Cell Death 1 Ligand 2)
    |
    cisplatin • carboplatin • oxaliplatin
    3d
    The efficacy and safety of the novel combination lenvatinib and pembrolizumab in endometrial cancer: A systematic review and single-arm meta-analysis. (PubMed, Heliyon)
    All grade adverse events occurred in 85 % and Grade 3 or worse adverse events occurred in 39 % of patients during the therapy whereas death occurred in 23.8 % during the treatment. The results of this meta-analysis concludes that although the combined treatment of a Lenvatinib and Pembrolizumab had a PFS and OS that was inferior to the standard therapy used to treat advanced and recurrent endometrial cancer, it is still a novel treatment and shows potential for further research with a greater sample size.
    Retrospective data • Review • Journal
    |
    MSI (Microsatellite instability)
    |
    Keytruda (pembrolizumab) • carboplatin • Lenvima (lenvatinib)
    4d
    A Study of Reduced Radiation Therapy and Standard-of-Care Chemotherapy in People With HPV-Positive Throat Cancer (clinicaltrials.gov)
    P2, N=121, Recruiting, Memorial Sloan Kettering Cancer Center | Trial completion date: Aug 2024 --> Aug 2025 | Trial primary completion date: Aug 2024 --> Aug 2025
    Trial completion date • Trial primary completion date
    |
    cisplatin • carboplatin • paclitaxel • 5-fluorouracil • albumin-bound paclitaxel
    4d
    Phase II Trial of Carboplatin +/- Tocilizumab for Metastatic Triple Negative and ER-low Breast Cancers (clinicaltrials.gov)
    P2, N=168, Recruiting, Kathy Miller | Trial completion date: Dec 2027 --> Dec 2026
    Trial completion date • Metastases
    |
    carboplatin • Actemra IV (tocilizumab)
    4d
    A Study of Subcutaneous (SC) Pembrolizumab Coformulated With Hyaluronidase (MK-3475A) vs Intravenous Pembrolizumab in Adult Participants With Metastatic Non-small Cell Lung Cancer (NSCLC) (MK-3475A-D77)-Japan Extension (clinicaltrials.gov)
    P3, N=378, Active, not recruiting, Merck Sharp & Dohme LLC | Recruiting --> Active, not recruiting
    Enrollment closed • Metastases
    |
    Keytruda (pembrolizumab) • cisplatin • carboplatin • albumin-bound paclitaxel • pemetrexed • Neupogen (filgrastim)
    4d
    Timing of Surgery After Neoadjuvant Chemotherapy for Advanced Ovarian Cancer (clinicaltrials.gov)
    P=N/A, N=250, Recruiting, Alexandria University
    New trial • Surgery • Metastases
    |
    carboplatin • paclitaxel
    4d
    Safety and Efficacy of Neoadjuvant Immunochemotherapy in Elderly Patients With Resectable Esophageal Cancer (clinicaltrials.gov)
    P2, N=68, Recruiting, Sichuan University
    New P2 trial • Combination therapy • Metastases
    |
    carboplatin • Tyvyt (sintilimab) • albumin-bound paclitaxel
    4d
    QUEEN-Dream: QL1706 Plus Chemotherapy as Neoadjuvant Therapy in Early High-Risk TNBC Breast Cancer (clinicaltrials.gov)
    P2, N=73, Not yet recruiting, Fudan University
    New P2 trial
    |
    carboplatin • albumin-bound paclitaxel • iparomlimab/tuvonralimab (PSB205)
    4d
    ESOPEC: Perioperative Chemotherapy Compared To Neoadjuvant Chemoradiation in Patients With Adenocarcinoma of the Esophagus (clinicaltrials.gov)
    P3, N=438, Active, not recruiting, University Hospital Schleswig-Holstein | Trial completion date: Jun 2024 --> Dec 2024 | Trial primary completion date: Apr 2023 --> May 2024
    Trial completion date • Trial primary completion date
    |
    carboplatin • paclitaxel • docetaxel • 5-fluorouracil • oxaliplatin • leucovorin calcium
    5d
    Evaluation of Programmed Death Ligand 1 (PDL1) Response to Treatment in Patient-derived Organoids and Immune-marker Positron Emission Tomography (PET) Scanning in Non-small Cell Lung Cancer (NSCLC) (clinicaltrials.gov)
    P1/2, N=40, Not yet recruiting, GlaxoSmithKline
    New P1/2 trial
    |
    PD-L1 (Programmed death ligand 1)
    |
    PD-L1 expression
    |
    Keytruda (pembrolizumab) • cisplatin • carboplatin • pemetrexed • Jemperli (dostarlimab-gxly)
    5d
    A Study of BMS-986406 as Monotherapy and Combination Therapies in Participants With Advanced Tumors (clinicaltrials.gov)
    P1, N=154, Active, not recruiting, Bristol-Myers Squibb | Recruiting --> Active, not recruiting
    Enrollment closed • Combination therapy • Metastases
    |
    Opdivo (nivolumab) • carboplatin • paclitaxel • pemetrexed • BMS-986406
    5d
    Real-World Multicenter Study of PD-1 Blockade in HIV-Associated Classical Hodgkin Lymphoma Across the United States. (PubMed, Clin Lymphoma Myeloma Leuk)
    Our findings support the use of PD-1 blockade in HIV-cHL for the same indications as the general population with cHL.
    Clinical • Journal • Real-world evidence • Real-world
    |
    CD4 (CD4 Molecule)
    |
    Keytruda (pembrolizumab) • Opdivo (nivolumab) • carboplatin • ifosfamide • etoposide IV • Adcetris (brentuximab vedotin)
    5d
    RFWD3 modulates response to platinum chemotherapy and promotes cancer associated phenotypes in high grade serous ovarian cancer. (PubMed, Front Oncol)
    In cell lines, reduction of RFWD3 expression led to increased sensitivity to interstrand crosslinking (ICL) inducing agents mitomycin C and carboplatin. In tumours, low RFWD3 expression was associated with increased tumour mutational burden, and complete response to platinum chemotherapy. RFWD3 expression varies in HGSOCs, which can lead to functional effects at both the cellular and tumour levels.
    Journal • Tumor mutational burden
    |
    TMB (Tumor Mutational Burden)
    |
    carboplatin • mitomycin
    6d
    Carboplatin, Paclitaxel and Gemcitabine Hydrochloride With or Without Bevacizumab After Surgery in Treating Patients With Recurrent Ovarian, Epithelial, Primary Peritoneal, or Fallopian Tube Cancer (clinicaltrials.gov)
    P3, N=1052, Active, not recruiting, National Cancer Institute (NCI)
    Trial completion date • Combination therapy • Surgery
    |
    MUC16 (Mucin 16, Cell Surface Associated)
    |
    Avastin (bevacizumab) • carboplatin • gemcitabine • paclitaxel • docetaxel
    6d
    The UPPROACH (Upfront Intensity Modulated Proton Beam Therapy) Approach (clinicaltrials.gov)
    P2, N=21, Recruiting, University of Maryland, Baltimore | Trial completion date: Sep 2026 --> Sep 2028 | Trial primary completion date: Sep 2025 --> Sep 2027
    Trial completion date • Trial primary completion date • Metastases
    |
    carboplatin • paclitaxel
    7d
    A Study of TSR-022 in Participants With Advanced Solid Tumors (AMBER) (clinicaltrials.gov)
    P1, N=475, Recruiting, Tesaro, Inc. | Trial completion date: Jul 2025 --> Apr 2027 | Trial primary completion date: Dec 2024 --> Apr 2025
    Trial completion date • Trial primary completion date • Metastases
    |
    Opdivo (nivolumab) • cisplatin • carboplatin • docetaxel • pemetrexed • Jemperli (dostarlimab-gxly) • cobolimab (TSR-022) • encelimab (TSR-033)
    7d
    A Study Using Risk Factors to Determine Treatment for Children With Favorable Histology Wilms Tumors (FHWT) (clinicaltrials.gov)
    P3, N=1656, Not yet recruiting, Children's Oncology Group
    New P3 trial
    |
    carboplatin • doxorubicin hydrochloride • cyclophosphamide • etoposide IV • irinotecan • vincristine • daunorubicin • dactinomycin
    7d
    Study to Evaluate Adverse Events, Change in Disease Activity, and How ABBV-706 Moves Through the Body When Intravenously (IV) Infused Alone or in Combination With IV Infused Budigalimab, Cisplatin, or Carboplatin in Adult Participants With Advanced Solid Tumors (clinicaltrials.gov)
    P1, N=350, Recruiting, AbbVie | Trial completion date: Oct 2025 --> May 2027
    Trial completion date • Adverse events • Combination therapy • Metastases
    |
    EGFR (Epidermal growth factor receptor) • SEZ6 (Seizure Related 6 Homolog)
    |
    EGFR mutation • IDH wild-type • SEZ6 expression
    |
    cisplatin • carboplatin • budigalimab (ABBV-181) • ABBV-706
    7d
    AcceleRET Lung: A Study of Pralsetinib Versus Standard of Care for First-Line Treatment of Advanced Non-Small Cell Lung Cancer (NSCLC) (clinicaltrials.gov)
    P3, N=223, Active, not recruiting, Hoffmann-La Roche | Trial completion date: Jun 2026 --> Jun 2025 | Trial primary completion date: Nov 2024 --> Jun 2025
    Trial completion date • Trial primary completion date • Metastases
    |
    RET (Ret Proto-Oncogene)
    |
    RET fusion
    |
    Keytruda (pembrolizumab) • cisplatin • carboplatin • gemcitabine • albumin-bound paclitaxel • pemetrexed • Gavreto (pralsetinib)
    7d
    NB compounds are potent and efficacious FOXM1 inhibitors in high-grade serous ovarian cancer cells. (PubMed, J Ovarian Res)
    NB compounds are potent, selective, and efficacious inhibitors of FOXM1 in HGSOC cells and are worthy of further investigation as HGSOC therapeutics.
    Journal
    |
    FOXM1 (Forkhead Box M1)
    |
    carboplatin
    7d
    MITO END-3: Efficacy of Avelumab immunotherapy according to molecular profiling in first-line endometrial cancer therapy. (PubMed, Ann Oncol)
    The MITO END-3 trial results suggest that TP53 mutation is associated with a poor effect of avelumab, while mutations of PTEN and ARID1A are related to a positive effect of the drug in patients with advanced endometrial cancer.
    Journal • Tumor mutational burden • BRCA Biomarker • MSi-H Biomarker • PD(L)-1 Biomarker • IO biomarker
    |
    TP53 (Tumor protein P53) • PIK3CA (Phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit alpha) • TMB (Tumor Mutational Burden) • BRCA1 (Breast cancer 1, early onset) • BRCA2 (Breast cancer 2, early onset) • MSI (Microsatellite instability) • PTEN (Phosphatase and tensin homolog) • ARID1A (AT-rich interaction domain 1A) • POLE (DNA Polymerase Epsilon)
    |
    TP53 mutation • BRCA2 mutation • BRCA1 mutation • TMB-H • MSI-H/dMMR • PIK3CA mutation • TP53 wild-type • PTEN mutation • ARID1A mutation • POLE mutation
    |
    carboplatin • paclitaxel • Bavencio (avelumab)
    9d
    OTUB2 silencing promotes ovarian cancer via mitochondrial metabolic reprogramming and can be synthetically targeted by CA9 inhibition. (PubMed, Proc Natl Acad Sci U S A)
    Importantly, pharmacological inhibition of CA9 substantially suppressed tumor growth and synergized with carboplatin in the treatment of OTUB2-silenced ovarian cancer. Thus, our study highlights the pivotal role of OTUB2/SNX29P2 in suppressing ovarian cancer development and proposes that targeting CA9-mediated glycolysis is an encouraging strategy for the treatment of ovarian cancer.
    Journal
    |
    HIF1A (Hypoxia inducible factor 1, alpha subunit) • VHL (von Hippel-Lindau tumor suppressor) • CA9 (Carbonic anhydrase 9) • SNX2 (Sorting Nexin 2)
    |
    carboplatin
    9d
    Study of SAR444881 Administered Alone and in Combination With Other Therapeutics in Participants With Advanced Solid Tumors (clinicaltrials.gov)
    P1/2, N=456, Recruiting, Sanofi | Trial completion date: Nov 2026 --> Feb 2027 | Trial primary completion date: Nov 2026 --> Feb 2027
    Trial completion date • Trial primary completion date • Combination therapy • Metastases
    |
    Keytruda (pembrolizumab) • Erbitux (cetuximab) • carboplatin • pemetrexed
    9d
    PRO1184-001: PRO1184 for Advanced Solid Tumors (clinicaltrials.gov)
    P1/2, N=374, Recruiting, ProfoundBio US Co. | N=134 --> 374 | Trial completion date: Sep 2025 --> Apr 2026 | Trial primary completion date: Jan 2025 --> Oct 2025
    Enrollment change • Trial completion date • Trial primary completion date • Metastases
    |
    HER-2 (Human epidermal growth factor receptor 2) • FOLR1 ( Folate receptor alpha )
    |
    HR positive • HER-2 negative • FOLR1 expression • HR positive + HER-2 negative • PTEN mutation + HR positive
    |
    Keytruda (pembrolizumab) • Avastin (bevacizumab) • carboplatin • rinatabart sesutecan (PRO1184)
    10d
    A Study of [177Lu]Lu-DOTA-TATE in Newly Diagnosed ES-SCLC Patients in Combination With Carboplatin, Etoposide and Atezolizumab (clinicaltrials.gov)
    P1/2, N=200, Recruiting, Novartis Pharmaceuticals | N=39 --> 200
    Enrollment change • Combination therapy
    |
    SSTR (Somatostatin Receptor)
    |
    SSTR positive
    |
    Tecentriq (atezolizumab) • carboplatin • etoposide IV • Lutathera (lutetium Lu 177 dotatate)
    10d
    REZILIENT3 (REsearching ZIpaLertinib In Egfr Non-small Cell Lung Cancer Tumors) (clinicaltrials.gov)
    P3, N=272, Recruiting, Taiho Oncology, Inc. | Trial completion date: May 2026 --> Aug 2026 | Trial primary completion date: Jan 2026 --> Jul 2026
    Trial completion date • Trial primary completion date • EGFR exon 20 • Metastases
    |
    EGFR (Epidermal growth factor receptor)
    |
    EGFR mutation
    |
    carboplatin • zipalertinib (CLN-081)
    10d
    A Study of Tobemstomig Plus Platinum-Based Chemotherapy vs Pembrolizumab Plus Platinum-Based Chemotherapy in Participants With Previously Untreated Non-Small Cell Lung Cancer (clinicaltrials.gov)
    P2, N=180, Recruiting, Hoffmann-La Roche | Active, not recruiting --> Recruiting
    Enrollment open • Metastases
    |
    PD-L1 (Programmed death ligand 1)
    |
    Keytruda (pembrolizumab) • carboplatin • paclitaxel • pemetrexed • tobemstomig (RG6139)
    11d
    Cabazitaxel, Carboplatin, and Cetrelimab Followed by Niraparib With or Without Cetrelimab for the Treatment of Aggressive Variant Metastatic Prostate Cancer (clinicaltrials.gov)
    P2, N=120, Active, not recruiting, M.D. Anderson Cancer Center | Recruiting --> Active, not recruiting
    Enrollment closed • Metastases
    |
    PD-L1 (Programmed death ligand 1) • TP53 (Tumor protein P53) • PTEN (Phosphatase and tensin homolog) • RB1 (RB Transcriptional Corepressor 1) • CEACAM5 (CEA Cell Adhesion Molecule 5)
    |
    PTEN mutation
    |
    carboplatin • Zejula (niraparib) • cabazitaxel • cetrelimab (JNJ-63723283)
    11d
    HIPEC: Trial Evaluating Feasibility and Quality of Life of Second Look Laparoscopy With Hyperthermic Intraperitoneal Chemotherapy (clinicaltrials.gov)
    P2, N=10, Recruiting, Wake Forest University Health Sciences | Trial primary completion date: Mar 2024 --> Aug 2024
    Trial primary completion date • HEOR
    |
    MUC16 (Mucin 16, Cell Surface Associated)
    |
    carboplatin
    11d
    Study of Pembrolizumab in Locally Advanced Esophageal Adenocarcinoma (clinicaltrials.gov)
    P2, N=42, Active, not recruiting, Weill Medical College of Cornell University | Trial completion date: Apr 2025 --> Sep 2026
    Trial completion date • Combination therapy • IO biomarker • Metastases
    |
    PD-L1 (Programmed death ligand 1)
    |
    PD-L1 expression
    |
    Keytruda (pembrolizumab) • carboplatin • paclitaxel
    11d
    TREBLE: Aumolertinib With Chemotherapy or Alone Compared With Osimertinib in Patients With Epidermal Growth Factor Receptor-Mutant Non-Small Cell Lung Cancer (clinicaltrials.gov)
    P3, N=8, Terminated, EQRx International, Inc. | Phase classification: P3b --> P3
    Phase classification • Metastases
    |
    EGFR mutation • EGFR L858R • EGFR exon 19 deletion • EGFR exon 20 insertion • EGFR L861Q • EGFR G719X • EGFR exon 20 mutation
    |
    cisplatin • Tagrisso (osimertinib) • carboplatin • gemcitabine • albumin-bound paclitaxel • pemetrexed • Ameile (aumolertinib)
    11d
    CRITICS-II: Multicentric Randomised Trial for Resectable Gastric Cancer (clinicaltrials.gov)
    P2, N=207, Active, not recruiting, The Netherlands Cancer Institute | Recruiting --> Active, not recruiting | Trial completion date: Jul 2029 --> Mar 2029 | Trial primary completion date: Jul 2024 --> Apr 2025
    Enrollment closed • Trial completion date • Trial primary completion date • Surgery
    |
    carboplatin • paclitaxel • docetaxel • capecitabine • oxaliplatin
    11d
    P53 Mutational Status and cf HPV DNA for the Management of HPV-associated OPSCC (clinicaltrials.gov)
    P2, N=195, Completed, UNC Lineberger Comprehensive Cancer Center | Active, not recruiting --> Completed
    Trial completion
    |
    Erbitux (cetuximab) • cisplatin • carboplatin • paclitaxel
    11d
    Phase III Study of AK112 for NSCLC Patients (clinicaltrials.gov)
    P3, N=420, Recruiting, Summit Therapeutics
    New P3 trial • Metastases
    |
    carboplatin • pemetrexed • ivonescimab (AK112)
    11d
    FIRST-NEC (GFPC 01-2022) - Combination of Durvalumab With Etoposide and Platinum (clinicaltrials.gov)
    P2, N=80, Not yet recruiting, Centre Leon Berard
    New P2 trial • IO biomarker
    |
    PD-L1 (Programmed death ligand 1) • RB1 (RB Transcriptional Corepressor 1)
    |
    PD-L1 expression • RB1 mutation
    |
    cisplatin • carboplatin • Imfinzi (durvalumab) • etoposide IV
    11d
    Chidamide+Decitabine Plus Anti-PD-1 Antibody in PD-1 Inhibitor Failed Patients With Classical Hodgkin Lymphoma. (clinicaltrials.gov)
    P2, N=60, Not yet recruiting, Chinese PLA General Hospital
    New P2 trial • IO biomarker
    |
    PD-1 (Programmed cell death 1)
    |
    carboplatin • gemcitabine • ifosfamide • etoposide IV • decitabine • pegylated liposomal doxorubicin • Adcetris (brentuximab vedotin) • Epidaza (chidamide)